REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort

MLA

Sophie Cousin, et al. “REGOMUNE: A Phase II Study of Regorafenib plus Avelumab in Solid Tumors—Results of the Oesophageal or Gastric Carcinoma (OGC) Cohort.” Journal of Clinical Oncology, vol. 40, June 2022, p. 4060. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.4060.

APA

Sophie Cousin, Jean Philippe Metges, Carine A. Bellera, Jean Philippe Guégan, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Lola Jade Palmieri, Michèle Kind, Isabelle Soubeyran, Jean Palussière, Alban Bessede, & Antoine Italiano. (2022). REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort. Journal of Clinical Oncology, 40, 4060. https://doi.org/10.1200/jco.2022.40.16_suppl.4060

Chicago

Sophie Cousin, Jean Philippe Metges, Carine A. Bellera, Jean Philippe Guégan, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, et al. 2022. “REGOMUNE: A Phase II Study of Regorafenib plus Avelumab in Solid Tumors—Results of the Oesophageal or Gastric Carcinoma (OGC) Cohort.” Journal of Clinical Oncology 40 (June): 4060. doi:10.1200/jco.2022.40.16_suppl.4060.